Robotic Endoscopy Devices Market: as Medtronic’s Hugo system finally clears FDA review for urologic procedures after years of international-only availability, the robotic endoscopy landscape is completing its transition from a single-vendor category defined almost entirely by Intuitive Surgical into a genuinely multi-vendor competitive field, so hospital purchasing decisions increasingly involve real platform comparison rather than a default single-vendor selection, and the pace at which each new entrant secures additional procedural indications beyond its first approval is becoming the clearest signal of how quickly the competitive field will actually broaden in practice.

The global robotic endoscopy devices market size was USD 3.22 Billion in 2025 and is expected to register a revenue CAGR of 9.8% during the forecast period. Market revenue growth is driven by factors such as Intuitive Surgical’s sustained procedure volume and revenue growth reinforcing the category’s established commercial base, Medtronic’s Hugo robotic-assisted surgery system securing its first United States regulatory clearance after years of international-only availability, and continued broadening of the competitive field as additional robotic platform vendors pursue regulatory approval in major markets. The first driving factor is Intuitive Surgical’s sustained procedure volume and revenue growth, reinforcing the established commercial base that anchors the broader robotic endoscopy category. Intuitive Surgical reported preliminary 2025 revenue of approximately USD 10.06 billion, a 21% increase from USD 8.35 billion in 2024, with worldwide da Vinci procedures growing approximately 18% for the year, confirming sustained double-digit growth across both revenue and procedure volume metrics. The second driving factor is Medtronic’s Hugo robotic-assisted surgery system securing FDA clearance for urologic surgical procedures in December 2025, its first United States regulatory approval after years of availability limited to international markets across more than 30 countries. Medtronic received FDA clearance for the Hugo RAS system for urologic surgical procedures including prostatectomy, nephrectomy, and cystectomy in December 2025, procedures that account for approximately 230,000 surgeries per year in the United States, with the company already planning submissions for general and gynaecologic surgery indications to follow. The third driving factor is continued broadening of the competitive field as additional robotic platform vendors pursue regulatory approval in major markets, extending hospital purchasing choice beyond the historically dominant single vendor. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a newly approved robotic platform’s first regulatory clearance widens its own addressable market as the vendor pursues additional procedural indications building on the same underlying platform, letting one initial approval compound into a broader addressable surgical specialty base over subsequent years rather than the vendor’s commercial opportunity remaining fixed at the scope of its first approval. Once a robotic endoscopy platform secures its first regulatory clearance for one procedural application, pursuing additional indications on the same underlying hardware and software architecture requires substantially less incremental investment than establishing an entirely new platform from scratch, so a vendor’s pace of indication expansion following its first approval is a leading indicator of how quickly its addressable market will compound over subsequent years. As a result, demand and revenue share are concentrating around vendors demonstrating rapid indication expansion following initial market entry, and the forecast tilts toward genuinely multi-indication competitive platforms rather than single-application entrants remaining confined to their first approved use. For instance, in December 2025, Medtronic, Ireland, received FDA clearance for its Hugo RAS system for urologic surgical procedures, its first United States approval following international use across more than 30 countries, and the company has already announced plans to pursue additional submissions for general and gynaecologic surgery indications, illustrating how a newly approved platform’s addressable market is expected to expand well beyond its initial procedural scope within a relatively short period. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is Intuitive Surgical’s continued double-digit revenue and procedure volume growth, confirming that the established robotic endoscopy commercial base remains a growing, not merely stable, category. Sustained double-digit growth in both revenue and underlying procedure volume, rather than revenue growth driven primarily by pricing alone, indicates genuine expanding clinical utilisation of robotic endoscopy technology across the installed base, so procedure volume growth and durable category-wide demand strength are directly linked. Intuitive Surgical reported preliminary 2025 revenue of approximately USD 10.06 billion, a 21% increase from USD 8.35 billion in 2024, with worldwide da Vinci procedures growing approximately 18% for the year according to the company’s January 2026 earnings release. The effect on the market is that the established robotic endoscopy commercial base continues expanding at a pace that sets a high growth benchmark for newly entering competitive platforms to match. These are some of the key factors driving revenue growth of the market.

The second driver is Medtronic’s Hugo robotic-assisted surgery system finally securing regulatory clearance in the United States, the market where robotic endoscopy commercial activity has historically concentrated most heavily. A robotic platform available internationally for years but lacking United States clearance cannot meaningfully compete for the largest single national robotic endoscopy market, and Hugo’s December 2025 clearance removes this specific competitive barrier, so United States regulatory clearance and genuine competitive market entry are directly linked for this category specifically. Medtronic received FDA clearance for the Hugo RAS system for urologic surgical procedures including prostatectomy, nephrectomy, and cystectomy in December 2025, procedures accounting for approximately 230,000 surgeries per year in the United States, following a supporting Expand URO clinical study that enrolled 137 patients and met its primary safety and effectiveness endpoints. The recent record shows the pace. Globally, the Hugo platform has already been used in tens of thousands of urologic, gynaecologic, and general surgery procedures across more than 30 countries on five continents, establishing a substantial international commercial track record ahead of its United States entry. The effect on the market is that the robotic endoscopy competitive landscape is genuinely broadening in the United States specifically, the market segment where competitive concentration has historically been most pronounced. These are some of the key factors driving revenue growth of the market.

“Medtronic’s Hugo RAS system received FDA clearance for urologic surgical procedures in December 2025, its first United States approval after years of use across more than 30 countries on five continents, with the company already planning submissions for general and gynaecologic surgery indications to follow.”

The third driver is the broader pattern of competitive field expansion as multiple robotic endoscopy platform vendors, beyond Medtronic specifically, continue pursuing regulatory approval across major markets. A hospital evaluating a robotic endoscopy platform purchase increasingly has genuine comparative options rather than a single-vendor default choice, and this expanding vendor field is what shifts purchasing dynamics from default selection toward genuine competitive evaluation on capability, service, and total cost of ownership. Additional robotic endoscopy platform vendors continue pursuing regulatory clearance across major markets, extending the competitive field beyond the historically dominant single vendor and giving hospitals a genuinely broader set of platform options to evaluate. The effect on the market is that robotic endoscopy platform purchasing decisions increasingly involve genuine multi-vendor comparison, changing the competitive dynamics that have defined this category for most of its commercial history. These are some of the key factors driving revenue growth of the market.

However, the robotic endoscopy devices market faces adoption constraints from the substantial capital investment required to acquire a robotic endoscopy platform, surgeon credentialing requirements that limit how quickly a hospital can realise full procedure volume, and switching cost from an established incumbent platform that limits how quickly newly available competitive alternatives can capture share. Because robotic endoscopy platforms represent a significant capital investment regardless of vendor, hospitals evaluating a new platform purchase, including newly available competitive alternatives such as Hugo RAS, must weigh this cost against existing capital commitments to incumbent platforms already installed, meaning capital budget cycles, not purely platform capability, often determine the pace of new vendor entry into any given hospital system. Surgeon credentialing and training requirements are a second constraint, because expanding robotic-assisted procedure volume on any platform, whether an established incumbent or a newly entering competitor, requires training and credentialing surgical teams before full clinical and financial benefit can be realised, and this training requirement applies equally to hospitals adopting a first robotic platform and those adding a second, competing platform alongside an existing one. Switching cost from an established incumbent platform is the third constraint, since a hospital that has already invested in training, credentialing, and instrument inventory for one robotic platform faces a genuine switching cost, including potential loss of accumulated procedural experience and instrument compatibility, when evaluating a newly available competitive alternative, even where the new platform offers comparable or superior capability on paper. These factors substantially limit robotic endoscopy devices market growth over the forecast period.

Based on product, the global robotic endoscopy devices market is segmented into robotic endoscopic surgical systems, robotic bronchoscopy platforms, and robotic endoscopy instruments and accessories. Robotic endoscopic surgical systems hold the largest revenue share, because they represent the highest-value capital equipment category and the primary competitive battleground between Intuitive Surgical and newly entering vendors such as Medtronic. Robotic bronchoscopy platforms are expected to register the fastest revenue growth rate in the global robotic endoscopy devices market over the forecast period, driven directly by Ion’s outsized procedure volume growth relative to broader surgical robotic procedure volume, which is why this category represents a distinct, faster-growing segment within the broader market.

Urologic surgery application is expected to account for a significantly large revenue share in the global robotic endoscopy devices market during the forecast period

Based on application, the global robotic endoscopy devices market is segmented into urologic surgery, general and gastrointestinal surgery, and pulmonary diagnostic procedures. Urologic surgery holds a significant revenue share, reflecting both Intuitive Surgical’s established urologic procedure base and Medtronic’s newly cleared Hugo RAS system entering this specific application first in the United States. Pulmonary diagnostic procedures are expected to register rapid revenue growth in the global robotic endoscopy devices market over the forecast period, driven directly by robotic bronchoscopy procedure volume growth, which is why this application represents one of the fastest-evolving categories within the broader market.

Multiport robotic-assisted technology is expected to account for the largest revenue share in the global robotic endoscopy devices market during the forecast period

Based on technology, the global robotic endoscopy devices market is segmented into multiport robotic-assisted and single-port/endoluminal robotic-assisted technology. Multiport robotic-assisted technology holds the largest revenue share, reflecting its established role across the majority of robotic endoscopic surgical procedures performed globally, including both da Vinci and Hugo platform procedures. Single-port/endoluminal robotic-assisted technology is expected to register rapid revenue growth in the global robotic endoscopy devices market over the forecast period, driven by expanding endoluminal bronchoscopy and single-port surgical platform adoption, which is why this technology tier represents an increasingly important area of platform differentiation.

Based on regional analysis, the robotic endoscopy devices market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest installed base of robotic endoscopy platforms globally, and because Intuitive Surgical’s established commercial base and Medtronic’s newly cleared Hugo RAS system both concentrate significant near-term competitive activity in the country. Medtronic’s December 2025 Hugo RAS FDA clearance addressed a specific application, urologic surgical procedures accounting for approximately 230,000 surgeries per year, that concentrates heavily within the United States hospital market. The concentration of the largest robotic endoscopy installed base and the most active near-term competitive entry activity in the United States also means the genuine multi-vendor competitive dynamics this market is developing will be most visible in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national robotic endoscopy devices markets within Europe. Medtronic’s Hugo RAS system has operated in Europe for several years prior to its United States clearance, giving the region a more established multi-vendor competitive dynamic already, and the region’s CE-marking regulatory pathway under the Medical Device Regulation sustains steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-established multi-vendor competitive maturity than by the newly emerging competitive dynamics playing out in the United States.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national robotic endoscopy devices markets within the region. Expanding robotic surgical infrastructure investment and rising minimally invasive procedure adoption in China and India are driving new robotic endoscopy demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national robotic endoscopy devices markets within the region. Private hospital networks in both countries are gradually expanding robotic-assisted surgical capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised robotic endoscopy platforms and instruments that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial robotic endoscopy devices markets within the GCC. The UAE is the most established robotic endoscopy devices market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building the surgical infrastructure that robotic endoscopy platform adoption depends on.